Cargando…
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Eculizumab, a monoclonal antibody (mAb) directed against complement protein C5, is considered to be the current standard of care for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. This study describes the generation and preclinical attributes of ALXN1...
Autores principales: | Sheridan, Douglas, Yu, Zhao-Xue, Zhang, Yuchun, Patel, Rekha, Sun, Fang, Lasaro, Melissa A., Bouchard, Keith, Andrien, Bruce, Marozsan, Andre, Wang, Yi, Tamburini, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897016/ https://www.ncbi.nlm.nih.gov/pubmed/29649283 http://dx.doi.org/10.1371/journal.pone.0195909 |
Ejemplares similares
-
Characterization of a monoclonal antibody to L1210 leukaemia.
por: Testorelli, C., et al.
Publicado: (1982) -
Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5
por: Cone, Josh, et al.
Publicado: (2023) -
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975) -
Development of cyclosporin A mediated immunity in L1210 leukaemia.
por: Slater, L. M., et al.
Publicado: (1991) -
1210. Recommendations for Screening and Diagnosis of Chagas Disease in the United States
por: Forsyth, Colin, et al.
Publicado: (2021)